Logo

ALLR

Allarity Therapeutics, Inc.

ALLR

Allarity Therapeutics, Inc. • NASDAQ
$1.33 ▲ 6.40% (+0.08)
Market Cap $19.32 M
52w High $2.35
52w Low $0.61
Dividend Yield 0%
P/E 0.15
Volume 120.64K
Outstanding Shares 14.52M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $2.518M ▼ $-2.806M ▼ 0% $-0.19 ▼ $-2.749M ▼
Q2-2025 $0 $4.133M ▲ $-2.32M ▲ 0% $-0.149 ▲ $-2.296M ▲
Q1-2025 $0 $3.036M ▼ $-2.732M ▲ 0% $-0.245 ▲ $-2.664M ▲
Q4-2024 $0 $7.317M ▼ $-7.453M ▲ 0% $-1.021 ▲ $-7.377M ▲
Q3-2024 $0 $12.313M $-11.59M 0% $-7.712 $-11.912M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $16.895M ▼ $20.796M ▼ $8.785M ▼ $12.011M ▼
Q2-2025 $17.801M ▼ $21.205M ▼ $9.038M ▼ $12.167M ▼
Q1-2025 $25.201M ▲ $29.73M ▲ $11.061M ▲ $18.669M ▲
Q4-2024 $19.533M ▲ $22.65M ▲ $10.839M ▲ $11.811M ▼
Q3-2024 $18.463M $20.378M $7.414M $12.964M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.806M ▼ $-3.41M ▲ $0 $2.31M ▲ $-906K ▲ $-3.41M ▲
Q2-2025 $-2.32M ▲ $-5.481M ▼ $0 $-2.565M ▼ $-9.903M ▼ $-5.481M ▼
Q1-2025 $-2.732M ▲ $-2.686M ▲ $0 ▲ $11.143M ▲ $8.171M ▲ $-2.686M ▲
Q4-2024 $-7.453M ▲ $-3.206M ▲ $-298K ▼ $4.235M ▼ $1.07M ▲ $-3.504M ▲
Q3-2024 $-11.59M $-5.443M $0 $4.868M $-770K $-5.443M

Five-Year Company Overview

Income Statement

Income Statement Allarity has effectively no revenue and has been running at a loss every year in the data provided. The losses are relatively small in absolute terms but persistent, reflecting the costs of running clinical trials and supporting the DRP® platform without any approved products on the market yet. Earnings per share figures look extreme because of repeated reverse stock splits, not because the underlying business suddenly changed. Overall, this is a typical income profile for a very early‑stage biotech: all expenses, no commercial income yet, and dependence on future trial success or deals to change that picture.

Balance Sheet

Balance Sheet The balance sheet is very small, with only a modest level of total assets and most of that sitting in cash. There is no financial debt reported, which reduces interest burden but also signals that the company mainly depends on issuing equity rather than borrowing. Shareholders’ equity is thin, which leaves only a limited cushion to absorb future losses. Combined with the company’s stage of development, this means the balance sheet looks fragile and sensitive to any setbacks in funding or clinical progress.

Cash Flow

Cash Flow Cash flows are consistently negative from operations, reflecting R&D and overhead spending without offsetting revenue. Free cash flow is also negative and closely tracks operating cash flow, since the company has essentially no capital spending. This pattern means the business is not self‑funding and must regularly tap external capital sources to keep going. The key question for the future is whether clinical and partnership milestones arrive fast enough to justify and support ongoing cash needs.

Competitive Edge

Competitive Edge Allarity occupies a narrow but potentially attractive niche in precision oncology, built around its DRP® drug response prediction platform. Its focus on mRNA expression rather than just gene mutations offers a differentiated way to match patients to drugs, which could be appealing to partners. Patents around specific DRP® signatures, such as for stenoparib, add some protection and help define a moat. However, the company is very small and competes in a space that includes much larger diagnostics and biotech players with more resources, making partnerships and validation especially important for its long‑term position.

Innovation and R&D

Innovation and R&D The company is highly R&D‑driven, with its main innovation being the DRP® platform used to tailor cancer treatments to the right patients. Its lead drug candidate, stenoparib, is supported by a drug‑specific DRP® test and has encouraging mid‑stage data plus regulatory support that could speed development. Allarity has streamlined its pipeline to concentrate on stenoparib and on combination‑therapy strategies, which sharpens focus but also increases dependence on a single key asset. Extending DRP® to other drugs, including antibody therapies, and licensing the platform to third parties adds upside potential but still needs to be proven out at scale. As with any clinical‑stage biotech, R&D success is uncertain and timing is hard to predict.

Summary

Allarity is an early‑stage precision oncology company with no product revenue yet, ongoing losses, and a very small but cash‑heavy balance sheet. Multiple reverse stock splits over a short period point to past dilution and underscore how reliant the firm has been on equity markets. On the positive side, the DRP® platform and stenoparib program give it a clear scientific focus and a differentiated approach in patient selection, with some regulatory tailwinds and partnership potential. On the risk side, the business is financially fragile, outcomes hinge heavily on a limited number of clinical programs, and it competes against much larger players in a demanding field. Overall, the story is highly innovation‑driven and high‑uncertainty, where future value depends largely on clinical results, regulatory decisions, and the company’s ability to secure supportive partnerships and funding.

NEWS

November 14, 2025 · 9:00 AM UTC

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

Read more

September 22, 2025 · 8:00 AM UTC

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

Read more

September 17, 2025 · 8:00 AM UTC

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

Read more